Vera Therapeutics filings document a Nasdaq-listed biotechnology company developing atacicept for serious immunological diseases, including IgA nephropathy. Form 8-K reports provide financial results, corporate updates, clinical and regulatory disclosures for the atacicept program, and material governance events such as board appointments, executive changes, and compensatory arrangements.
Proxy materials describe annual meeting matters, director elections, auditor ratification, advisory executive compensation votes, board committee structure, and related governance practices. The company’s filings also identify its Class A common stock registered on The Nasdaq Stock Market and disclose equity awards issued under director compensation and inducement grant arrangements.
Vera Therapeutics, Inc. reported second quarter 2026 results and highlighted a major regulatory milestone. The company received FDA accelerated approval for TRUTAKNA in adult patients with primary IgA nephropathy (IgAN) at risk for disease progression and has begun a U.S. commercial launch. TRUTAKNA is the first approved therapy that inhibits both BAFF and APRIL, with Phase 3 ORIGIN data showing a 46% proteinuria reduction from baseline at 36 weeks and a 42% reduction versus placebo, plus a 68% reduction in galactose-deficient IgA1 and hematuria resolution in 81% of affected patients.
For the quarter ended June 30, 2026, Vera reported a net loss of $109.5 million, or $1.52 per share, compared with a $76.5 million loss, or $1.20 per share, a year earlier. Operating expenses rose to $112.5 million from $80.1 million, reflecting higher research and development and general and administrative spending. As of June 30, 2026, the company held $499.2 million in cash, cash equivalents and marketable securities and has access to up to $425 million under a debt facility, subject to conditions, to support its TRUTAKNA launch and ongoing clinical programs. Management expects the ORIGIN 3 final efficacy analysis in Q3 2026, an sBLA filing in Q4 2026, and is targeting potential full approval in 2027.
State Street Corporation reported beneficial ownership of Vera Therapeutics Inc. common stock. It reported beneficial ownership of 4,148,786 shares of common stock, representing 5.8% of the class. State Street reported no sole voting or dispositive power over these shares, with shared voting power over 3,996,044 shares and shared dispositive power over 4,148,786 shares. The holdings are attributed to investment adviser subsidiaries including SSGA Funds Management, Inc. and several State Street Global Advisors entities.
Boman Nancy Lee reported acquisition or exercise transactions in this Form 4 filing.
Vera Therapeutics, Inc. reported equity awards to Chief Regulatory Officer Nancy Lee Boman. On August 3, 2026 she received stock options over 63,011 Class A shares at $32.23 per share, expiring August 2, 2036, plus 44,987 RSUs under the 2024 Inducement Plan vesting from 2027 to 2030, each award subject to continuous service.
Vera Therapeutics, Inc. has filed an initial statement of beneficial ownership on Form 3 for Nancy Lee Boman, who serves as Chief Regulatory Officer. The filing does not report any transactions or derivative positions and references Exhibit 24 as a Power of Attorney authorizing the filing.
BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of Class A stock of Vera Therapeutics, Inc. BlackRock reports beneficial ownership of 5,340,522 shares, representing 7.4% of the Class A shares outstanding.
BlackRock has sole voting power over 5,247,811 shares and sole dispositive power over 5,340,522 shares, with no shared voting or dispositive power. Various underlying clients have rights to dividends or sale proceeds, but no individual client holds more than five percent of Vera’s outstanding common shares.
Vera Therapeutics, Inc. director and CEO Marshall Fordyce reported open-market sales of an aggregate 46,250 shares of Class A common stock on July 7, 2026. The shares were sold at weighted-average prices reflecting trade ranges from $40.39 to $43.97 per share.
The filing notes the sales were made under a written trading plan adopted on January 9, 2026 that meets Rule 10b5-1(c) requirements. Following these transactions, Fordyce holds 151,994 shares directly, plus 99,081 shares held by a trust and 122,949 shares held by a GRAT, both reported as indirect ownership.
Vera Therapeutics, Inc. is changing its regulatory leadership. Effective August 3, 2026, Nancy Bowman, M.D., Ph.D. will become the company’s Chief Regulatory Officer. On the same date, current Chief Regulatory Officer William Turner will step down from that role and move into a new position as Special Advisor for Regulatory Affairs.
The company disclosed this leadership transition under the category covering departures and appointments of certain officers.
Vera Therapeutics reported that the U.S. Food and Drug Administration has granted accelerated approval for its drug TRUTAKNA™ (atacicept-vymj) as of July 7, 2026. The therapy is approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy who are at risk for disease progression.
This represents Vera’s transition into a commercial-stage company for IgA nephropathy, with an FDA-cleared product aimed at a serious kidney disease where reducing protein in the urine can help slow long-term damage.
Vera Therapeutics, Inc. director, president and CEO Marshall Fordyce reported open-market sales of a total of 18,500 shares of Class A Common Stock on June 23, 2026. The sales were executed at weighted-average prices of $38.43 and $37.93 per share.
The filing states these transactions were made under a pre-arranged Rule 10b5-1(c) trading plan adopted on January 9, 2026, with individual trades occurring between $37.43 and $38.315. After the sales, Fordyce directly holds 198,244 shares and indirectly holds 99,081 shares through a trust and 122,949 shares through a GRAT.
VERA notice reports an intended resale of 74,000 shares via an exercise of stock options on 06/23/2026. The filing also discloses prior 10b5-1 sales by Marshall Fordyce of 18,500 shares on 05/12/2026 and 22,951 shares on 04/14/2026.